1. 1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses. (September 2015) Authors: Jung, K.H.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Azim, H.A.; Pivot, X.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Gligorov, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1968 Routine practice use of Oncotype Dx assay in French breast cancer patients. (September 2015) Authors: Wassermann, J.; Toledano, A.; Gligorov, J.; Conforti, R.; Grapin, J.P.; Benothman, S.; Spano, J.P.; Khayat, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial. (April 2021) Authors: Gligorov, J.; Pivot, X.; Ataseven, B.; De Laurentiis, M.; Llombart, A.; Jung, K.H.; Manikhas, A.; Azim, H.A.; Alexandrou, A.; Gupta, K.; Herraez-Baranda, L.; Tosti, N.; Restuccia, E. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. (18th October 2016) Authors: Pierga, J.-Y.; Bidard, F.-C.; Autret, A.; Petit, T.; Andre, F.; Dalenc, F.; Levy, C.; Ferrero, J.-M.; Romieu, G.; Bonneterre, J.; Lerebours, F.; Bachelot, T.; Kerbrat, P.; Campone, M.; Eymard, J.-C.; Mouret-Reynier, M.-A.; Gligorov, J.; Hardy-Bessard, A.-C.; Lortholary, A.; Soulie, P. Journal: Annals of oncology Issue: Volume 28:Number 1(2017) Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. (November 2017) Authors: Pivot, X.; Verma, S.; Fallowfield, L.; Müller, V.; Lichinitser, M.; Jenkins, V.; Sánchez Muñoz, A.; Machackova, Z.; Osborne, S.; Gligorov, J. Journal: European journal of cancer Issue: Volume 86(2017) Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. O012: Clinical utility of a simple risk assessment model for cancer-associated thrombosis to identify breast cancer patients at high risk of symptomatic central venous catheter-related thrombosis. Issue 175 (March 2019) Authors: Frere, C.; Espie, M.; Gligorov, J.; Elias, A.; Dupre, P.F.; Villiers, S.; Giacchetti, S.; Debourdeau, P.; Farge, D. Journal: Thrombosis research Issue: Issue 175(2019)Supplement 1 Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer. (March 2015) Authors: Gligorov, J.; De Laurentiis, M.; Verrill, M.; Jung, K.H.; Azim, H.A.; Ataseven, B.; Al-Sakaff, N.; Heinzmann, D.; Shing, M.; Pivot, X. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. (September 2017) Authors: Pivot, X.; Spano, J.P.; Espie, M.; Cottu, P.; Jouannaud, C.; Pottier, V.; Moreau, L.; Extra, J.M.; Lortholary, A.; Rivera, P.; Spaeth, D.; Attar-Rabia, H.; Benkanoun, C.; Dima-Martinez, L.; Esposito, N.; Gligorov, J. Journal: European journal of cancer Issue: Volume 82(2017) Page Start: 230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PONDx: a prospective multicenter French study of the 21-gene assays: impact on treatment selection in patients with high-risk breast cancer. (March 2017) Authors: Gligorov, J.; Bourgeois, H.; Dohollou, N.; Dewas, S.; Wassermann, J.; Tixier, L.; Bourgeois, D.; Genet, D.; Coscas, Y.; Khayat, D. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. (September 2017) Authors: Gligorov, J.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Jung, K.H.; Azim, H.A.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Pivot, X. Journal: European journal of cancer Issue: Volume 82(2017) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗